Britain’s decision to leave the European Union threatens to undermine its position as a center for drug research and UK patients could fall behind others in Europe in getting access to new drugs, Roche’s chief executive said.
Currently, new drugs are approved by the European Medicines Agency, but in future Britain may have to set up its own drug approval system and the country could move to the back of the queue for new medicines, industry executives say.
Source: Reuters
Filed Under: Drug Discovery
